A Novel Molecular Target for Seizure Therapy and Neuroprotection
UAB Research Foundation
posted on 11/08/2011
Epilepsy affects approximately 2.5 million people in the United States, and results in an estimated annual cost of $15.5 billion in healthcare. It is estimated that one-third of epileptics are unresponsive to current pharmacological therapies, and therefore there exists an urgent need for better treatments. Researchers at the University of Alabama at Birmingham (UAB) have identified a novel molecular target, RGS4, a molecule regulating G-protein signaling, that enhances neuroprotection. This discovery makes possible the development of new therapies for epileptics and people with neural damage including brain injury and stroke.
would cause seizure suppression, and prevent neuronal damage and recurrent spontaneous seizures
would have fewer side-effects than current anti-epileptic therapeutics which target sodium/calcium channels and GABAergic transmission, and
would also be beneficial for neuropathic pain because the mechanism modulates adenosine’s protective effect against neuroinflammation.
File Number: U2010-0078
Disease: Central Nervous System
Find more innovations